Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
1 Page
English

Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day

Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

Description

Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day PR Newswire NEW YORK, June 19, 2012 NEW YORK, June 19, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc.

Subjects

Informations

Published by
Reads 15
Language English
Keryx Biopharmaceuticals Announces Live
Webcast of Upcoming Analyst Day
PR Newswire
NEW YORK, June 19, 2012
NEW YORK
,
June 19, 2012
/PRNewswire/ -- Keryx Biopharmaceuticals, Inc.
(Nasdaq: KERX) today announced that its upcoming Analyst Day will be webcast
live on
Thursday, June 21, 2012
at
4:30 pm ET
. Scheduled speakers include:
Julia Lewis, M.D.
, will provide her perspective on the Zerenex (ferric citrate)
Phase 3 clinical program and the potential Zerenex product profile.
-- Professor of Medicine, Division of Nephrology, Vanderbilt University School of
Medicine.
Geoffrey Block, M.D.
, will discuss the potential for Zerenex in pre-dialysis.
-- Director of Research, Denver Nephrology and Associate Clinical Professor in
Medicine, University of Colorado Health Sciences Center.
David Goldfarb, M.D.
, will discuss the potential importance of citrate.
-- Chief, Nephrology Division, NY Campus of NY Harbor Health Care Veterans
Affairs System and Professor of Medicine & Physiology, NYU School of Medicine.
To access the live audio webcast, please visit the Company's Investor Relations
section of their website (http://investors.keryx.com). An archived version of the
webcast will become available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral,
ferric iron-based compound that has the capacity to bind to phosphate and
form non-absorbable complexes. The Phase 3 clinical program of Zerenex for
the treatment of hyperphosphatemia (elevated phosphate levels) in patients
with end-stage renal disease is being conducted pursuant to a Special Protocol
Assessment (SPA) agreement with the FDA. Keryx is headquartered in
New York
City
.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: +1-212-531-5965
E-mail: lfischer@keryx.com